EP1855650B1 - Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation - Google Patents
Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation Download PDFInfo
- Publication number
- EP1855650B1 EP1855650B1 EP06707447A EP06707447A EP1855650B1 EP 1855650 B1 EP1855650 B1 EP 1855650B1 EP 06707447 A EP06707447 A EP 06707447A EP 06707447 A EP06707447 A EP 06707447A EP 1855650 B1 EP1855650 B1 EP 1855650B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- metronidazole
- solution
- medium
- water
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims description 101
- 229960000282 metronidazole Drugs 0.000 title claims description 100
- 238000000034 method Methods 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title description 7
- 229940042129 topical gel Drugs 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 99
- 239000002609 medium Substances 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 38
- 229920000642 polymer Polymers 0.000 claims description 26
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 18
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 17
- 238000004090 dissolution Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003755 preservative agent Substances 0.000 claims description 14
- 239000008346 aqueous phase Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 150000007942 carboxylates Chemical class 0.000 claims description 9
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 9
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 9
- 229960002216 methylparaben Drugs 0.000 claims description 9
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 9
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 9
- 229960003415 propylparaben Drugs 0.000 claims description 9
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 description 45
- 229960001484 edetic acid Drugs 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 5
- 229940043234 carbomer-940 Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 201000004700 rosacea Diseases 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 241001303601 Rosacea Species 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- -1 poly(acrylic acids) Polymers 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 206010000501 Acne conglobata Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000003493 Rhinophyma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Definitions
- the present invention relates to a novel method for preparing metronidazole-based aqueous gels which are useful in particular as topical dermatological compositions, especially for the treatment of dermatoses, such as rosacea.
- Metronidazole or 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, is the compound of the formula (I) :
- Metronidazole is an acknowledged antibacterial and antiparasitic agent useful for the treatment of many conditions. This compound is known in particular as being particularly effective in the treatment of skin disorders such as rosacea.
- Rosacea is a chronic skin condition which affects mainly adults. It is a type of dermatosis with recurrent symptoms, including in particular erythemas, papules, pustules, rhinophymas and/or telangiectasias, which manifests itself mainly in the region of the nose, the cheeks and the forehead.
- metronidazole is preferably administered by the topical route.
- administration by the systemic route in particular by the oral route, leads, in most cases, to undesirable side effects, such as gastrointestinal intolerance or vaginitis, to which other chronic disorders may also be added in the case of a long-term administration.
- metronidazole which are mainly oil-based compositions, in particular creams (oil-in-water emulsions) or ointments (in particular compositions based on petroleum jelly).
- metronidazole is dissolved in the oily phase.
- oil-based compositions have the advantage of being able to contain large quantities of metronidazole in the solubilised state, available for topical application.
- they are found, in practice, to be poorly suited to dermatological use. Indeed, they require the presence of ingredients, in particular oils, emulsifiers or surfactants, which are found to exhibit comedogenic, acneigenic, drying and/or irritating properties for the skin.
- patients treated with compositions of this type often feel sensations of burning or urtication.
- compositions in the form of aqueous gels which do not require the presence of comedogenic, acneigenic, drying and/or irritating agents present in the abovementioned oil-based compositions.
- compositions of US 4,837,378 comprise metronidazole in an aqueous phase gelled with a polymeric gelling agent, such as a polycarboxylated vinyl polymer.
- a polymeric gelling agent such as a polycarboxylated vinyl polymer.
- compositions of US 4,837,378 may additionally comprise additional agents, such as propylene glycol which improve the efficacy of administration of metronidazole, or preservatives such as methylparaben or propylparaben. Where appropriate, these additives are added to the preformed solution of metronidazole in water, and then the mixture obtained is mixed with the gelling polymer.
- additional agents such as propylene glycol which improve the efficacy of administration of metronidazole, or preservatives such as methylparaben or propylparaben.
- aqueous gels of US 4,837,378 have numerous advantages, in addition to the fact that they do not comprise ingredients capable of leading to the side effects observed with the abovementioned oil-based compositions. In particular, they allow better control of application and a uniform distribution of the active ingredient. Furthermore, they act as prolonged-release systems, which gradually deliver the active ingredient topically, in a therapeutically effective amount for a prolonged period.
- One aim of the present invention is to provide aqueous gels for the topical administration of metronidazole having the advantages of the compositions of US 4,837,378 , but additionally having increased stability over time.
- the expression "stability" of an aqueous metronidazole gel is understood to mean its capacity to retain its gel structure over a long period, with metronidazole mainly in the dissolved and non-crystallized state. It is considered that a gel is all the more stable if the period during which is retains its gel structure with metronidazole mainly in the dissolved state is long.
- the subject of the present invention is a method for preparing a stable aqueous gel based on metronidazole, comprising the successive steps consisting in:
- metronidazole-based aqueous gel is understood to mean a gelled aqueous phase, preferably monophasic, and containing metronidazole.
- this gel contains metronidazole as sole active ingredient with a cosmetic or pharmaceutical effect.
- the metronidazole is present in the gel in a therapeutically effective quantity.
- This metronidazole content may vary according to the application envisaged for the gel, but it advantageously remains between 0.25% and 1.0% by mass, and it is typically of the order of 0.75 to 0.8% by mass relative to the total mass of the aqueous gel.
- the inventors have demonstrated that, during the preparation of such an aqueous gel, a dissolution of the metronidazole in a medium initially containing water and propylene glycol, of the M medium type in step (B), makes it possible to obtain aqueous metronidazole gels having high stability.
- the work by the inventors has in particular made it possible to establish that the use of this specific step of dissolution in a propylene glycol-based medium makes it possible to obtain gels with increased stability compared to the gels obtained according to the methods of US 4,837,378 , where the metronidazole is first dissolved in water, and where propylene glycol is introduced into the medium afterwards.
- the method of the invention requires in general much less propylene glycol than the method of US 4,837,378 , where this compound is introduced in an amount of 7.9% by mass into the metronidazole dispersion.
- This use of propylene glycol in a limited quantity constitutes another advantage of the method of the invention, in particular from an economic point of view.
- the stabilizing effect observed by the inventors is at least partly due to the fact that a mixture of water and propylene glycol allows a very good solubilization of metronidazole, in particular when the water and the propylene glycol are present in the abovementioned advantageous ranges, whereas a lower solubilization is obtained when the propylene glycol is introduced after the dissolution of the metronidazole in water, even when the propylene glycol is post-introduced in large quantities as in the method of US 4,837,378 .
- the inventors have demonstrated that while metronidazole has a solubility in water of the order of 0.78%, water/propylene glycol mixtures can bring about higher solubilities.
- medium M formed in step (A) comprises a preservative in addition to the water and the propylene glycol, this preservative being preferably present in a quantity effective to inhibit microbial growth in the gel during its storage.
- this preservative is chosen from the paraben family.
- a mixture of methylparaben and of propylparaben is found to be particularly advantageous to this effect.
- the presence of preservatives such as parabens in medium M also makes it possible, in some cases, to improve the solubilization of metronidazole during step (B), and it also leads to an improvement in the stability of the gel obtained.
- Medium M most often consists of a mixture of water, propylene glycol and optionally preservatives of the abovementioned type, excluding any other compound. Nevertheless, the presence of other chemical species is not excluded insofar as they do not hamper effective solubilization of metronidazole in step (B).
- the medium of step (A) may for example comprise ethylene diamine tetraacetic acid (EDTA) or one of its salts as additional ingredient, although it is most often preferable for this acid to be introduced after the dissolution of metronidazole in step (B).
- EDTA ethylene diamine tetraacetic acid
- EDTA which is commonly used in dermatological compositions, is useful in particular for chelating metal cations which may be present as impurities in the composition, which makes it possible in particular to avoid undesirable side effects in some patients.
- EDTA also inhibits the phenomena of browning of the composition which can occur during storage of the gel, in particular when the pH of the gel is of the order of 3.5 to 5.4.
- the gel prepared according to the method of the present invention advantageously contains EDTA, preferably in an amount of 0.01 to 0.1% by mass, and typically in an amount of the order of 0.05% by mass.
- step (B) the dissolution of metronidazole in this medium M is carried out at a temperature greater than 40°C, this temperature being advantageously at least 45°C, and most preferably at least 50°C, in particular in order to obtain optimum dissolution of the metronidazole. It is preferable, moreover, that this temperature remains less than 70°C, and preferably less than or equal to 60°C, in particular for economic reasons. Thus, this temperature is typically of the order of 50 to 55°C.
- step (B) the metronidazole is introduced into medium M with a mass ratio (metronidazole/medium M) which is most often between 0.5 and 2.5, for example between 0.8 and 2.2, typically between 1 and 2.
- step (B) simply consists in dissolving metronidazole in medium M prepared in step (A).
- step (B) consists in dissolving, in a first instance, the metronidazole in medium M prepared in step (A), and then in diluting the metronidazole solution by adding water.
- the water is in general introduced alone as dilution medium, but it is not impossible, according to a particular embodiment, for the water for dilution to be introduced in the form of an aqueous solution containing water-soluble compounds, for example EDTA.
- this step leads to a solution S of metronidazole in aqueous medium being obtained.
- This solution S has, in general, a metronidazole concentration greater than 0.5% by mass, and it is typically between 0.7 and 2.5% by mass, relative to the total mass of solution S.
- the metronidazole is mainly in solubilized form.
- less than 1%, and most often less than 0.5%, or even less than 0.1%, of the total mass of metronidazole is in the insolubilized state.
- Step (C) of mixing solution S with the gelling polymer may be carried out by any means known to persons skilled in the art.
- the gelling agent may in particular be simply introduced into solution S.
- the polymer may first be mixed with water, and optionally with other water-soluble compounds such as EDTA or pH-regulating agents such as sodium hydroxide, to form a pre-gel, this pre-gel then being mixed with solution S.
- the gelling polymer used in step (C) may be any polymer suitable for gelling an aqueous phase in order to form a gel of uniform structure.
- This is preferably a water-dispersible polymer, having high affinity for water, this polymer being preferably a polymer having free carboxyl groups which are completely or partly neutralizable in the form of carboxylates with a base.
- Particularly advantageous gelling polymers in step (C) are vinyl polymers with water-dispersible carboxylate groups, in particular poly(acrylic acids) neutralized with a base.
- Most particularly advantageous are polymers having a molecular mass of the order of 1 250 000 to 4 000 000.
- suitable poly(acrylic acids) are for example the poly(acrylic acids) crosslinked with compounds of the polyalkenyl polyether type, such as carbomers, such as the polymers available from the company Goodrich under the trade name Carbopol 934, 940 or 941, Carbopol 940 being most particularly preferred.
- carbomers such as the polymers available from the company Goodrich under the trade name Carbopol 934, 940 or 941, Carbopol 940 being most particularly preferred.
- the neutralization of the carboxyl groups in the gelling polymers described above may be carried out by adding to the gel a base, for example aqueous ammonia, NaOH or organic amines, such as alkylamines (for example methylamine, ethylamine) or alternatively dialkylamines, trialkylamines, alkanolamines or dialkanolamines.
- a base for example aqueous ammonia, NaOH or organic amines, such as alkylamines (for example methylamine, ethylamine) or alternatively dialkylamines, trialkylamines, alkanolamines or dialkanolamines.
- alkylamines for example methylamine, ethylamine
- dialkylamines trialkylamines
- alkanolamines or dialkanolamines alkanolamines
- the final pH of the gel may vary widely according to the application envisaged. However, most often, this pH is of the order of 3
- the gelling polymer is introduced in step (C) in a sufficient quantity to lead in fine to a gel being obtained.
- this quantity is sufficient to produce a viscosity suitable for topical application of the gel, in particular for dermatological applications.
- the gelling polymer is advantageously introduced in step (C) in a quantity such that its final content in the gel is between 0.2% and 7.0% by mass, preferably between 0.5% and 1.5% by mass, relative to the total mass of the gel, this content being typically of the order of 0.6% by mass.
- steps (A) to (B) of the method of the invention consist in:
- steps (A1) to (C1) advantageously consist in:
- steps (A2) to (C2) of the method of the invention consist in:
- steps (A2) to (C2) consist in:
- the method of the invention makes it possible to obtain metronidazole-based aqueous gels which have a high stability during their storage.
- These particularly stable compositions constitute a second subject of the present invention.
- compositions in particular aqueous gels, which can be obtained according to one of the methods described above.
- compositions are in particular suitable for the preparation of a medicament intended for application by the topical route for the prophylactic or therapeutic treatment of skin conditions, in particular in human beings.
- these compositions are in particular suitable for the treatment of rosacea, or of various forms of acne, such as acne vulgaris, acne conglobata or nodulocystic acne, or certain types of dermatitis, such as perioral or seborrhoeic dermatitis.
- Example 1 Method for preparing an aqueous gel G1 based on metronidazole
- aqueous gel G1 based on metronidazole was prepared under the following conditions:
- a homogeneous solvent medium based on water and propylene glycol was thus obtained.
- the solution (s1) obtained was gelled by adding 6.5 kg of Carbomer 940 (marketed by Goodrich), in a dry form.
- the gelling agent was introduced gradually, with stirring with the aid of a scraper at 25 revolutions per minute and a turbine at 3000 revolutions per minute, for 30 minutes.
- Example 2 Method for preparing an aqueous gel G2 based on metronidazole
- aqueous gel G2 based on metronidazole was prepared under the following conditions:
- a mixture of 1.04 kg of methylparaben and 0.26 kg of propylparaben was gradually added to 36 kg of propylene glycol, with stirring. The stirring was maintained until complete dissolution of the methylparaben and propylparaben had been obtained.
- the medium thus obtained was introduced into 429 litres of purified water, kept stirred in a 700 litre jacketed reactor, at a temperature of between 50 and 55°C. The mixing was carried out with the aid of a dispersing device.
- a homogeneous solvent medium based on water and propylene glycol was thus obtained.
- a solution of 1.3 kg of NaOH in 13 litres of water was then introduced into the medium.
- the medium was then subjected to stirring at 30 revolutions per minute for 90 minutes.
- This gelled phase was mixed with the solution (s2) of metronidazole obtained above, at 55°C.
- the mixture was prepared by introducing the solution (s1) into the gelled aqueous phase, allowing the medium to cool to 33°C, and then mixing with coaxial stirring at 30 revolutions per minute for 120 minutes.
- Example 3 Method for preparing an aqueous gel G3 based on metronidazole
- aqueous gel based on metronidazole was prepared under the following conditions:
- the mixture thus obtained was introduced into 660 litres of purified water, kept stirred at 1000 revolutions per minute in a reactor kept at a temperature of 53°C +/- 2°C.
- a homogeneous solvent medium based on water and propylene glycol was thus obtained.
- a solution of 2 kg of NaOH in 20 litres of purified water was then introduced into the medium.
- the medium was then subjected to stirring at 1000 revolutions per minute, under a -0.6b vacuum, for 90 minutes.
- the solution (s1) of metronidazole prepared above was mixed with this gelled phase.
- the mixture was prepared by introducing the solution (s3) prepared above into the gelled aqueous phase, allowing the medium to cool to 31°C +/- 2°C, and then mixing, with coaxial stirring at 30 revolutions per minute under a -0.8b vacuum, for 120 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Claims (11)
- Procédé de préparation d'un gel aqueux stable à base de métronidazole, comprenant les étapes successives consistant à :(A) former un milieu solvant M comprenant de l'eau et du propylène glycol ;(B) dissoudre le métronidazole dans ce milieu solvant M, cette dissolution étant éventuellement suivie par une dilution du milieu obtenu par addition d'eau, ce par quoi on obtient une solution S de métronidazole ; puis(C) mélanger la solution S obtenue avec un polymère gélifiant ayant des groupements carboxyliques libres qui sont entièrement ou partiellement neutralisables sous forme de carboxylates, en une quantité suffisante pour assurer la gélification de la composition.
- Procédé selon la revendication 1, où le rapport massique propylène glycol/eau dans le milieu M formé dans l'étape (A) est compris entre 2% et 15%.
- Procédé selon la revendication 1 ou selon la revendication 2, où le milieu .M formé dans l'étape (A) contient en outre un agent conservateur.
- Procédé selon la revendication 3, où l'agent conservateur est un mélange de méthylparabène et de propylparabène.
- Procédé selon l'une quelconque des revendications précédentes, où, dans l'étape (B), la dissolution du métronidazole dans le milieu M est réalisée à une température comprise entre 40 et 60°C.
- Procédé selon l'une quelconque des revendications précédentes, où, dans l'étape (B), le métronidazole est introduit dans le milieu M avec un rapport massique (métrodinazole/milieu M) compris entre 0,5 et 2,5 %.
- Procédé selon la revendication 6, dans laquelle la solution de métronidazole S obtenue à l'issue de l'étape (B) a une concentration en métronidazole supérieure à 0,5 % en masse, par rapport à la masse totale de la solution aqueuse.
- Procédé selon l'une quelconque des revendications précédentes, où, dans la solution de métronidazole S obtenue à l'issue de l'étape (B), moins de 1% de la masse totale du métronidazole est à l'état insolubilisé.
- Procédé selon la revendication 1, comprenant les étapes consistant à :(a1) former un milieu M comprenant de 96% à 98% d'eau, de 2% à 5% de propylène glycol, de 0 à 2% d'agents conservateurs, et de 0 à 2% d'EDTA ;(b1) dissoudre du métronidazole dans le milieu aqueux M ainsi formé, avec un rapport massique métronidazole/milieu M compris entre 0,5% et 1%, de façon à former une solution S de métronidazole ; puis (c1) introduire dans la solution S obtenue un polymère gélifiant porteur de groupements carboxyliques libres neutralisés sous forme de carboxylates, avec un rapport massique polymère gélifiant/solution S compris entre 0,5% et 1%.
- Procédé selon l'une quelconque des revendications 1 à 9, comprenant les étapes consistant à :(A2) former un milieu M comprenant de l'eau et du propylène glycol ;(B2) dissoudre le métronidazole dans le milieu aqueux M ainsi formé, de façon à former une solution S' de métronidazole, puis ajouter de l'eau à cette solution S', ce par quoi on obtient une solution S de métronidazole ; puis(C2) mélanger la solution S obtenue à une phase aqueuse gélifiée contenant un polymère gélifiant porteur de groupements carboxyliques libres neutralisés sous forme de carboxylates, en une quantité suffisante pour assurer la gélification de la totalité de la composition.
- Procédé selon ta revendication 10, comprenant les étapes consistant à :(a2) former un milieu M comprenant 90% à 95% d'eau, 5% à 10% de propylène glycol, et de 0 à 0,5% d'agents conservateurs ;(b2) dissoudre du métronidazole dans le milieu aqueux M ainsi formé, avec un rapport massique métronidazole/milieu M compris entre 1,5% et 2,5% de façon à former une solution S' de métronidazole, puis ajouter de l'eau à cette solution S' de façon à obtenir une solution S de métronidazole ayant une teneur en métronidazole de 1% à 2,2% ; puis(c2) mélanger la solution S obtenue à une phase aqueuse gélifiée contenant 98% à 99,5% d'eau, 0,5% à 1,5% d'un polymère gélifiant porteur de groupements carboxyliques libres neutralisés sous forme de carboxylates, avec un rapport massique phase aqueuse gélifiante/solution S compris entre 1,4 1 et 1,8 : 1.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06707447T PL1855650T3 (pl) | 2005-02-25 | 2006-02-16 | Wodny miejscowy żel o wysokiej stabilności, oparty na metronidazolu, i sposób otrzymywania |
SI200631537T SI1855650T1 (sl) | 2005-02-25 | 2006-02-16 | Vodni topikalni gel z visoko stabilnostjo na osnovi metronidazola in postopek priprave |
CY20131100208T CY1113783T1 (el) | 2005-02-25 | 2013-03-05 | Υδατικη τοπικη γελη υψηλης σταθεροτητας με βαση την μετρονιδαζολη και μεθοδος παρασκευης |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501949A FR2882552B1 (fr) | 2005-02-25 | 2005-02-25 | Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation |
US67163505P | 2005-04-15 | 2005-04-15 | |
PCT/EP2006/002074 WO2006089804A1 (fr) | 2005-02-25 | 2006-02-16 | Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1855650A1 EP1855650A1 (fr) | 2007-11-21 |
EP1855650B1 true EP1855650B1 (fr) | 2012-12-05 |
Family
ID=35044713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06707447A Active EP1855650B1 (fr) | 2005-02-25 | 2006-02-16 | Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090215849A1 (fr) |
EP (1) | EP1855650B1 (fr) |
JP (1) | JP2008531517A (fr) |
KR (1) | KR20070112139A (fr) |
CN (1) | CN101128185A (fr) |
AR (1) | AR054228A1 (fr) |
AU (1) | AU2006218043B2 (fr) |
BR (1) | BRPI0608044A2 (fr) |
CA (1) | CA2598031A1 (fr) |
DK (1) | DK1855650T3 (fr) |
ES (1) | ES2400502T3 (fr) |
FR (1) | FR2882552B1 (fr) |
MX (1) | MX2007010179A (fr) |
PL (1) | PL1855650T3 (fr) |
PT (1) | PT1855650E (fr) |
RU (1) | RU2409346C2 (fr) |
SI (1) | SI1855650T1 (fr) |
WO (1) | WO2006089804A1 (fr) |
ZA (1) | ZA200707558B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013033759B1 (pt) | 2011-06-28 | 2021-05-25 | Chemo Research Sl | forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol |
CN113476397B (zh) * | 2021-07-12 | 2022-11-18 | 海南海神同洲制药有限公司 | 一种甲硝唑凝胶及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
JPH0825878B2 (ja) * | 1987-03-20 | 1996-03-13 | ガルデルマ エスアー | 局所的メトロニダゾール製剤 |
US5536743A (en) * | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
JP2533723B2 (ja) * | 1992-12-28 | 1996-09-11 | 東興薬品工業株式会社 | 速乾性ゲルタイプ手指消毒剤 |
FR2700952B1 (fr) * | 1993-01-29 | 1995-03-17 | Oreal | Nouvelles compositions cosmétiques ou dermopharmaceutiques sous forme de gels aqueux modifiés par addition de microsphères expansées. |
FR2722098B1 (fr) * | 1994-07-06 | 1996-08-23 | Cird Galderma | Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine |
IN188720B (fr) * | 1997-11-06 | 2002-11-02 | Panacea Biotec Ltd | |
IL138889A0 (en) * | 1998-04-17 | 2001-11-25 | Bertek Pharm Inc | Topical formulations for the treatment of nail fungal diseases |
US7074832B2 (en) * | 2001-09-24 | 2006-07-11 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US7368122B1 (en) * | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
US6846837B2 (en) * | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
AR041021A1 (es) * | 2002-08-22 | 2005-04-27 | Novartis Consumer Health Sa | Composicion topica |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
-
2005
- 2005-02-25 FR FR0501949A patent/FR2882552B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-16 KR KR1020077019197A patent/KR20070112139A/ko not_active Application Discontinuation
- 2006-02-16 RU RU2007135364/15A patent/RU2409346C2/ru not_active IP Right Cessation
- 2006-02-16 EP EP06707447A patent/EP1855650B1/fr active Active
- 2006-02-16 SI SI200631537T patent/SI1855650T1/sl unknown
- 2006-02-16 PT PT67074476T patent/PT1855650E/pt unknown
- 2006-02-16 CN CNA2006800059009A patent/CN101128185A/zh active Pending
- 2006-02-16 PL PL06707447T patent/PL1855650T3/pl unknown
- 2006-02-16 MX MX2007010179A patent/MX2007010179A/es active IP Right Grant
- 2006-02-16 AU AU2006218043A patent/AU2006218043B2/en not_active Ceased
- 2006-02-16 JP JP2007556571A patent/JP2008531517A/ja active Pending
- 2006-02-16 BR BRPI0608044-8A patent/BRPI0608044A2/pt not_active IP Right Cessation
- 2006-02-16 ES ES06707447T patent/ES2400502T3/es active Active
- 2006-02-16 DK DK06707447.6T patent/DK1855650T3/da active
- 2006-02-16 WO PCT/EP2006/002074 patent/WO2006089804A1/fr active Application Filing
- 2006-02-16 CA CA002598031A patent/CA2598031A1/fr not_active Abandoned
- 2006-02-23 AR AR20060100653A patent/AR054228A1/es unknown
-
2007
- 2007-08-21 US US11/892,292 patent/US20090215849A1/en not_active Abandoned
- 2007-09-03 ZA ZA200707558A patent/ZA200707558B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PL1855650T3 (pl) | 2013-04-30 |
WO2006089804A1 (fr) | 2006-08-31 |
ES2400502T3 (es) | 2013-04-10 |
SI1855650T1 (sl) | 2013-05-31 |
RU2007135364A (ru) | 2009-03-27 |
MX2007010179A (es) | 2007-09-18 |
ZA200707558B (en) | 2008-10-29 |
CN101128185A (zh) | 2008-02-20 |
KR20070112139A (ko) | 2007-11-22 |
AR054228A1 (es) | 2007-06-13 |
FR2882552A1 (fr) | 2006-09-01 |
CA2598031A1 (fr) | 2006-08-31 |
US20090215849A1 (en) | 2009-08-27 |
PT1855650E (pt) | 2013-02-28 |
EP1855650A1 (fr) | 2007-11-21 |
BRPI0608044A2 (pt) | 2009-11-03 |
JP2008531517A (ja) | 2008-08-14 |
RU2409346C2 (ru) | 2011-01-20 |
AU2006218043B2 (en) | 2012-02-02 |
FR2882552B1 (fr) | 2008-12-26 |
AU2006218043A1 (en) | 2006-08-31 |
DK1855650T3 (da) | 2013-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190125776A1 (en) | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | |
WO2019014380A1 (fr) | Plates-formes pour administration topique de médicaments et leurs procédés de préparation | |
IE850146L (en) | Topical drug release system | |
JPH0338250B2 (fr) | ||
EP1467744A2 (fr) | Compositions aqueuses contenant du metronidazole | |
JP2011504912A (ja) | アダパレンゲルの製造方法 | |
KR950003919B1 (ko) | 국소용 메트로니다졸 제제의 제조방법 | |
WO2010047831A1 (fr) | Formulations de gel de métronidazole stables | |
US8563535B2 (en) | Combination composition comprising benzoyl peroxide and adapalene | |
EP3097907B1 (fr) | Formulation de gel comprenant des agents analgésiques et anesthésiants | |
CA2429205C (fr) | Formulations dermatologiques | |
EP1855650B1 (fr) | Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation | |
US20100004338A1 (en) | Topical gel composition comprising azelaic acid | |
AU2016233317A1 (en) | Treatment of acne vulgaris with sequential topical formulations comprising antimicrobial organic acid anions in alkaline phase | |
JP2005527561A (ja) | 小動物用の注射可能な獣医用組成物 | |
WO2016137411A1 (fr) | Composition de spray topique comprenant de l'ibuprofène et de la lidocaïne | |
JPWO2010109544A1 (ja) | 核酸を有効成分とする外用剤組成物 | |
EP2340016B1 (fr) | Formule topique de dihydrate propionate 3-(2,2,2-trimethylhydrazinium) | |
JPS63287721A (ja) | 消炎鎮痛ゲル剤 | |
JP2006117539A (ja) | 油性軟膏剤 | |
JPH11199484A (ja) | 外用剤組成物 | |
WO2022003168A1 (fr) | Formulation de gel topique contenant de l'asimadoline | |
JP2014156481A (ja) | 核酸を有効成分とする外用剤組成物 | |
JP2005008569A (ja) | ジフルプレドナート製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070925 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20071213 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PEDRASSI, GERALD,RESIDENCE LES GRANDES FUTAIES Inventor name: ZARIF, LEILA Inventor name: BRZOKEWICZ, ALAIN |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PEDRASSI, GERALD Inventor name: ZARIF, LEILA Inventor name: BRZOKEWICZ, ALAIN |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BRZOKEWICZ, ALAIN Inventor name: ZARIF, LEILA Inventor name: PEDRASSI, GERALD |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 586872 Country of ref document: AT Kind code of ref document: T Effective date: 20121215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602006033448 Country of ref document: DE Effective date: 20130131 |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20130219 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2400502 Country of ref document: ES Kind code of ref document: T3 Effective date: 20130410 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E007504 Country of ref document: EE Effective date: 20130226 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20130400466 Country of ref document: GR Effective date: 20130418 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20130906 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 14884 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E017811 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006033448 Country of ref document: DE Effective date: 20130906 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BG Payment date: 20141212 Year of fee payment: 10 Ref country code: MC Payment date: 20141219 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20150210 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20150209 Year of fee payment: 10 Ref country code: CZ Payment date: 20150205 Year of fee payment: 10 Ref country code: PT Payment date: 20150216 Year of fee payment: 10 Ref country code: DK Payment date: 20150210 Year of fee payment: 10 Ref country code: EE Payment date: 20150203 Year of fee payment: 10 Ref country code: IE Payment date: 20150210 Year of fee payment: 10 Ref country code: SK Payment date: 20150119 Year of fee payment: 10 Ref country code: HU Payment date: 20150115 Year of fee payment: 10 Ref country code: LU Payment date: 20150204 Year of fee payment: 10 Ref country code: IS Payment date: 20150106 Year of fee payment: 10 Ref country code: LT Payment date: 20150122 Year of fee payment: 10 Ref country code: RO Payment date: 20150114 Year of fee payment: 10 Ref country code: CH Payment date: 20150213 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20150120 Year of fee payment: 10 Ref country code: SE Payment date: 20150212 Year of fee payment: 10 Ref country code: AT Payment date: 20150126 Year of fee payment: 10 Ref country code: GR Payment date: 20150114 Year of fee payment: 10 Ref country code: TR Payment date: 20150213 Year of fee payment: 10 Ref country code: LV Payment date: 20150202 Year of fee payment: 10 Ref country code: PL Payment date: 20150210 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20150211 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20150202 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM4D Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: MM4A Ref document number: E007504 Country of ref document: EE Effective date: 20160229 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20160229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 586872 Country of ref document: AT Kind code of ref document: T Effective date: 20160216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160831 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160217 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160930 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 14884 Country of ref document: SK Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20160301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160217 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160816 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160217 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160905 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20161013 Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160301 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20130400466 Country of ref document: GR Effective date: 20160905 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210112 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20210305 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220216 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240219 Year of fee payment: 19 Ref country code: GB Payment date: 20240219 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240220 Year of fee payment: 19 |